Ignite Creation Date:
2024-05-05 @ 11:39 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00106002
Status:
COMPLETED
Last Update Posted:
2009-06-01
First Post:
2005-03-18
Brief Title:
Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
A Phase II Study of Alimta as First Line Chemotherapy for Advanced or Metastatic Breast Cancer
Status:
COMPLETED
Status Verified Date:
2009-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purposes of this study are to determine whether pemetrexed can help patients with metastatic cancer that has spread to other parts of the body breast cancer to determine any side effects that may be associated with the drug to determine how much pemetrexed should be given to patients and to collect DNA for future research regarding metastatic breast cancer The collection of DNA is optional to the patient
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| H3E-US-S045 | None | None | None |